Stockscreener 앱 받기
23.06
6.02%
1.31
시간 외 거래:
23.07
0.01
+0.04%
전일 마감가:
$21.75
열려 있는:
$22.59
하루 거래량:
900.58K
Relative Volume:
0.38
시가총액:
$286.10M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-15.79
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+0.44%
1개월 성능:
+1.45%
6개월 성능:
+3,311%
1년 성능:
+1,806%
1일 변동 폭
$22.01
$23.98
1주일 범위
$21.60
$23.98
52주 변동 폭
$0.432
$37.38
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
23.06 | 388.40M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Why Nektar Therapeutics Stock Popped 6% on Friday - MSN
Can Nektar Therapeutics expand into new marketsElite Return Strategy Watch - thegnnews.com
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - MSN
Nektar Therapeutics Q2 2025 Earnings: Revenue Exceeds Estimates, EPS Loss Wider Than Expected, Cash and Investments Down to $175.9 Million - AInvest
Nektar Therapeutics Q2 Earnings: Revenue Down, Net Loss Up, but Cash Position Strong and FDA Fast Track Designation for Rezpegaldesleukin - AInvest
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $98 to $120 - 富途牛牛
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Nektar Therapeutics 2025 Q2 Earnings Loss Narrows by 21.5% - AInvest
Nektar Therapeutics (NKTR): A High-Risk, High-Reward Biotech Play in the Treg Space - AInvest
Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia Areata - Dermatology Times
Nektar Therapeutics: Operational Efficiency Gains Amid Revenue Decline—A Path to Profitability or a Temporary Reprieve? - AInvest
Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance - TipRanks
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
Transcript : Nektar Therapeutics, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss By Investing.com - Investing.com Australia
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss - Investing.com
Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments - TipRanks
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Str - GuruFocus
Nektar Therapeutics Reports Q2 2025 Financial Results - TipRanks
Nektar (NKTR) Q2 Revenue Falls 52% - The Globe and Mail
Nektar Therapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
Nektar Therapeutics Q2 2025 Earnings: Revenue at $11.2M Beats Es - GuruFocus
Nektar Therapeutics: Strategic Pipeline Progress and Financial Prudence Position for Long-Term Value Creation - AInvest
Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c - StreetInsider
Nektar Reports Game-Changing Atopic Dermatitis Results, Secures FDA Fast Track Status and $115M Funding - Stock Titan
Nektar gets FDA fast track status for alopecia areata drug - MSN
Nektar: Q2 Earnings Snapshot - Norwalk Hour
Nektar Therapeutics Files Amendments To Increase Authorized Common Stock From 300M To 390M Shares And Implement 1-For-15 Reverse Stock Split Effective June 8, 2025; Split-Adjusted Trading To Begin June 9, 2025 - 富途牛牛
Nektar Gears Up to Report Q2 Earnings: What's in the Cards? - MSN
FDA grants fast track designation to Nektar’s rezpegaldesleukin in alopecia areata - PMLiVE
What is the dividend policy of Nektar Therapeutics stockExplosive portfolio gains - Jammu Links News
What drives Nektar Therapeutics stock priceSignificant capital appreciation - Jammu Links News
Should I hold or sell Nektar Therapeutics stock in 2025Achieve consistent profits with proven methods - Jammu Links News
Does Nektar Therapeutics stock perform well during market downturnsAchieve breakthrough growth with proven strategies - Jammu Links News
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53% - uk.finance.yahoo.com
What are analysts’ price targets for Nektar Therapeutics in the next 12 monthsStrongest growth potential - Jammu Links News
What institutional investors are buying Nektar Therapeutics stockTrack stocks with high upside potential easily - Jammu Links News
Published on: 2025-08-03 06:56:13 - Jammu Links News
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets - Eastern Progress
Nektar Therapeutics' Q2 2025 Earnings: A Pivotal Moment for Its Immuno-inflammatory Pipeline and Financial Resilience - AInvest
Nektar soars on atopic dermatitis data, leads drug developer gainers in Q2 - BioWorld MedTech
Signal strength of Nektar Therapeutics stock in tech scannersSmart Trade Plans With Risk Protection Explained - metal.it
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):